Search

Displaying results 2461 - 2470 of 10000 in total
  1. Drug

    Polysilicone-15

    go.drugbank.com/drugs/DB11271
    Approved

    The compound is a colorless to pale yellow viscous liquid which is soluble in organic solvents of medium polarity and insoluble in water [L2796, L2797, L2799, F87, F88, F89]. … When included in various other cosmetic shampoos, conditioners, or hairsprays the compound also functions as an effective photostabilizer of the product [L2796, L2797, L2799, F87, F88, F89].

    Mixtures: OHUI SUN SCIENCE Perfect Sunblock Blue EX plus
  2. Drug

    Piretanide

    go.drugbank.com/drugs/DB02925
    Approved

    Piretanide (INN, trade names Arelix, Eurelix, Tauliz) has been synthesized in 1973 at Hoechst AG (Germany) as a loop diuretic compound by using a then-new method for introducing cyclic amine residues in … an aromatic nucleus in the presence of other aromatically bonded functional groups.

    Mixtures: RAMITANID AL 5MG/6MG, RAMIPRIL HEXAL PL PIR5/6MGProducts: PIRETANID HEXAL 3MG, PIRETANID HEXAL 6MG
  3. Drug

    Hesperidin

    go.drugbank.com/drugs/DB04703
    ApprovedInvestigational

    Hesperidin is a flavan-on glycoside found in citrus fruits.

    Mixtures: Rose Hips 500plus Nu Life, DAFLON TABLET 500 mg
  4. Drug

    Piperaquine

    go.drugbank.com/drugs/DB13941
    ApprovedInvestigational

    Piperaquine is an antimalarial agent first synthesized in the 1960's and used throughout China [A31550]. … Eurartesim was first authorized for market by the European Medicines Agency in October 2011.

    Mixtures: EURARTESIM 320 MG/40 MG FILM COATED TABLETS, D-ARTEPP
  5. Drug

    LI-301

    go.drugbank.com/drugs/DB05509
    Experimental

    It has a novel mode of action combining both the light effect of a Selective Serotonin Reuptake Inhibitor ("SSRI")(most likely antagonistic at 5HT1a receptors) and antagonism at mu-opioid receptors. … LI 301 is an orally bio-available compound delivered in a fast melt mechanism with taste masking enabling it to be taken anytime without water.

  6. Drug

    Genistein

    go.drugbank.com/drugs/DB01645
    Investigational

    It has been investigated in clinical trials as an alternative to classical hormone therapy to help prevent cardiovascular disease in postmenopausal women [A14417]. … An isoflavonoid derived from soy products. It inhibits protein-tyrosine kinase and topoisomerase-II (DNA topoisomerases, type II) activity and is used as an antineoplastic and antitumor agent.

    Mixtures: CALCIDAY G 1200 MG/800 IU/50 MG EFERVESAN TABLET, 45 ADET, OSMEGA 600 MG/400 IU/25 MG EFERVESAN TABLET, 30 ADETCategories: Compounds used in a research, industrial, or household setting
  7. Drug

    Lasofoxifene

    go.drugbank.com/drugs/DB06202
    ApprovedInvestigationalWithdrawn

    It gained approval by European Commission in March 2009. … Later Fablyn was developed as a result of a research collaboration between Pfizer and Ligand Pharmaceuticals with a newly submitted New Drug Application in 2008.

  8. Drug

    Tegaserod

    go.drugbank.com/drugs/DB01079
    ApprovedWithdrawn

    Novartis' brand name Zelnorm (tegaserod) had originally received approval from the US FDA in 2002 for the treatment of irritable bowel syndrome with constipation (IBS-C). … [L5918,F4229] It was, however, voluntarily withdrawn from widespread use in the US market in 2007 after concerns arose over the possibility that tegaserod could potentially cause dangerous cardiovascular

  9. Drug

    Lurbinectedin

    go.drugbank.com/drugs/DB12674
    ApprovedInvestigational

    [A214331] On June 15, 2020, the FDA granted accelerated approval and orphan drug designation to lurbinectedin for the treatment of adult patients with metastatic SCLC who have experienced disease progression … [L14336] This accelerated approval is based on the rate and duration of therapeutic response observed in ongoing clinical trials and is contingent on the verification of these results in confirmatory trials

    Products: ZEPZELCA POWDER FOR SOLUTION FOR INFUSION 4MG/VIAL
  10. Drug

    Gedatolisib

    go.drugbank.com/drugs/DB11896
    ApprovedInvestigational

    breast cancer without a PIK3CA mutation detected, following progression on or after at least one line of endocrine therapy in the metastatic setting. … [L63796,L63927] The PI3K/AKT/mTOR pathway is a long-standing target in the breast cancer setting, with previously approved agents acting on a single node of it (i.e. PI3Kα, AKT, or mTORC1).